- Home
- BIOA vs CGEN Comparison
BIOA vs CGEN Comparison
Compare BIOA & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIOA
- CGEN
- Stock Information
- Founded
- BIOA 2015
- CGEN 1993
- Country
- BIOA United States
- CGEN Israel
- Employees
- BIOA N/A
- CGEN N/A
- Industry
- BIOA Biotechnology: Pharmaceutical Preparations
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BIOA Health Care
- CGEN Health Care
- Exchange
- BIOA Nasdaq
- CGEN Nasdaq
- Market Cap
- BIOA 177.1M
- CGEN 142.4M
- IPO Year
- BIOA 2024
- CGEN 2000
- Fundamental
- Price
- BIOA $5.14
- CGEN $2.25
- Analyst Decision
- BIOA Hold
- CGEN Strong Buy
- Analyst Count
- BIOA 3
- CGEN 1
- Target Price
- BIOA $18.00
- CGEN $4.00
- AVG Volume (30 Days)
- BIOA 959.0K
- CGEN 898.9K
- Earning Date
- BIOA 02-15-2025
- CGEN 03-04-2025
- Dividend Yield
- BIOA N/A
- CGEN N/A
- EPS Growth
- BIOA N/A
- CGEN N/A
- EPS
- BIOA N/A
- CGEN 0.02
- Revenue
- BIOA N/A
- CGEN $59,852,000.00
- Revenue This Year
- BIOA N/A
- CGEN $57.27
- Revenue Next Year
- BIOA N/A
- CGEN N/A
- P/E Ratio
- BIOA N/A
- CGEN $125.59
- Revenue Growth
- BIOA N/A
- CGEN 698.03
- 52 Week Low
- BIOA $3.85
- CGEN $1.35
- 52 Week High
- BIOA $26.62
- CGEN $3.03
- Technical
- Relative Strength Index (RSI)
- BIOA N/A
- CGEN 81.70
- Support Level
- BIOA N/A
- CGEN $1.92
- Resistance Level
- BIOA N/A
- CGEN $2.16
- Average True Range (ATR)
- BIOA 0.00
- CGEN 0.15
- MACD
- BIOA 0.00
- CGEN 0.07
- Stochastic Oscillator
- BIOA 0.00
- CGEN 88.90
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.